RUPINDER GREWAL: Open Payments
NPI 1689136392 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,420 in 69 payments from 17 companies in 2025. Trend: 2023 $217 · 2024 $1,621 · 2025 $1,420
Food & beverage: $1,420
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $364 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $149 |
| Lundbeck LLC | 6 | $117 |
| Noven Therapeutics, LLC | 5 | $97 |
| Axsome Therapeutics, Inc. | 4 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $89 |
| Neurocrine BioSciences, Inc. | 3 | $74 |
| Janssen Pharmaceuticals, Inc | 3 | $64 |
| Alkermes, Inc. | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
Products named: VRAYLAR, TRINTELLIX, REXULTI, Xelstrym, Auvelity, CAPLYTA, INGREZZA, SPRAVATO.
Industry payments across IL — which companies pay providers there.
